Management characterized 2025 as a year of deliberate repositioning rather than a continuation, focusing on strengthening the operating foundation over top-line growth.

The transition of manufacturing to KDI Precision Manufacturing was executed to ensure long-term supply chain reliability and improved structural margins rather than immediate cost savings.

The company sharpened its strategic identity around the 'cardiorenal continuum,' targeting patients where cardiac and renal conditions are interrelated and precision volume management is critical.

International operations were rationalized by exiting the European Union and other inconsistent markets to reduce cash burn and redirect resources to more predictable geographies.

Performance in the fourth quarter was bolstered by a 208% increase in U.S. console sales, reflecting successful penetration within targeted accounts and clinical pull.

Operational discipline was reinforced by terminating the expensive REVERSE-HF clinical trial to preserve approximately $3 million in cash for more immediate strategic priorities.

The 2026 strategy shifts from structural refinement to execution, with a primary objective of translating strategic clarity into more predictable commercial performance.

Management plans to relaunch the 'Clarity' product mid-year 2026 following the integration of the Rendiatek acquisition.

The pediatric program will advance through the development of 'Vivien,' a novel solution supported by non-dilutive NIH grant funding and expanded intellectual property.

Commercial focus for 2026 will prioritize increasing utilization within existing accounts, particularly in critical care and pediatric nephrology, rather than broad-based expansion.

Financial priorities for the coming year include maintaining gross margin consistency, enhancing forecasting precision, and disciplined capital deployment.

The company ended 2025 with $1.2 million in cash and no outstanding debt, following $7 million in net proceeds raised through financing activities during the year.

Full-year net loss of $17.5 million included a $6.4 million non-cash warrant valuation expense and $300,000 in executive severance.

The Rendiatek acquisition was strategically motivated by its bedside urine output monitoring technology, which addresses acute kidney injury in approximately 60% of critical care patients.

A product recall and prior quality issues necessitated the shift to contract manufacturing to stabilize the supply chain and product quality.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

The direct sales team has been restored to its budgeted level of 24 individuals, including account managers and clinical specialists.

Management expects to maintain this headcount through 2026, focusing heavily on the critical care ICU opportunity where cardiorenal issues are prevalent.

The acquisition provides a differentiated bedside technology to measure renal output and electrolytes, serving as a key biomarker for kidney health.

This technology replaces the need to send samples to a lab, providing immediate data to clinicians treating patients coming off heart-lung machines.

While console sales grew significantly in Q4, the primary focus for 2026 is driving deeper penetration and increased utilization within existing accounts.

Many current heart failure accounts are being targeted for expansion into critical care applications using the Aquadex and Rendiatek platforms.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.